A phase III trial with patients with BRAF-mutated melanoma showed a significant prolongation of overall survival if treated with Trametinib, a Mitogen-activated protein kinase kinase (MEK) inhibitor, together with Dabrafenib, a BRAF inhibitor [59]. This evidence concerns the gene WNK2 and melanoma.